HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
The PERT Consortium shared a proud post on X:
”We’re excited to share enrollment for HI-PEITHO is now complete! With 544 patients enrolled across 72 sites in the United States in Europe, this landmark trial compares EKOS (Ultrasound Assisted Thrombolysis) with Anticoagulation vs Anticoagulation Alone in the treatment of intermediate-high risk PE patients. The study was a collaboration between The PERT Consortium, University Medical Center Mainz, and Boston Scientific. We extend our congratulations to all investigators and enrollment sites involved in this one-of-a-kind trial that will inform strategies for PE treatment around the world.”
Learn more abouth the HI-PEITHO here.
Enrollment for the HIPEITHO trial has successfully concluded, with 544 patients enrolled across 72 clinical sites in the United States and Europe.
In HIPEITHO Trial, the pivotal, multicenter study compares ultrasound-assisted catheter-directed thrombolysis using the EKOS system plus anticoagulation versus anticoagulation alone in patients with intermediate-high risk pulmonary embolism (PE).
A collaboration between The PERT Consortium, University Medical Center Mainz, and Boston Scientific, HIPEITHO trial represents a major step forward in evaluating treatment strategies for PE.
The results are expected to significantly inform clinical decision-making and global PE management.
Congratulations to all investigators and sites for their contribution to this groundbreaking trial!
Find the latest scientific advancements in thrombosis management featured in Hemostasis Today.
-
Jul 27, 2025, 06:41Clot Classroom: Meaningful Insights into Renal Vein Thrombosis Awareness
-
Jul 27, 2025, 06:04Unlocking Hematology: Dr. Houssein Safa’s Game-Changing Educational Series for Internists
-
Jul 26, 2025, 18:32From Jawless Fish to Mammals: Clotting Cascade Origins
-
Jul 26, 2025, 15:12ISTH 2025 Guidelines: Submit Your Topic Proposals by September 8
-
Jul 26, 2025, 15:05Beyond the Needle: The BUTTERFLY Study Eases LMWH Burden
-
Jul 27, 2025, 06:16Can a Single DNA Change Decide If You’ll Have a Boy or a Girl? Scientists Think So
-
Jul 26, 2025, 18:21C-Terminal VWF Variants in von Willebrand Disease: Functional Insights from the D4-C6 Domains
-
Jul 26, 2025, 17:271 Hypothesis, Multiple Implications: Adenoviral Vector Vaccines and Thrombosis with Thrombocytopenia Syndrome
-
Jul 25, 2025, 05:40Why Is Gene Therapy Uptake in Hemophilia Slower Than Expected
-
Jul 25, 2025, 05:27New Insights: Diagnosing Pulmonary Embolism in COPD Patients
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Jul 13, 2025, 15:35World’s First Liver Transplant for Plasminogen Deficiency Performed at KFSHRC
-
Jul 26, 2025, 16:14Cesar Garrido: Forging Strong Partnerships on WHA78 ''Global Health Equity'' Event
-
Jul 23, 2025, 15:34Don't Miss the Hemophilia B Virtual Event on July 29 – Sign Up Now!
-
Jul 23, 2025, 11:05Haemnet Gives Voice to Parents Facing the Challenges of Childhood Bleeding Disorders
-
Jul 23, 2025, 10:43From Blood Clot Survivor to NFL History: Trey Smith’s Record Deal
-
Jul 22, 2025, 16:48How Children See Blood Clots: World Thrombosis Day Shares Artwork from Young Artists